nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2014-18-6-66-73nefr-56Research ArticleСтатьиОСТРОЕ ПОВРЕЖДЕНИЕ ПОЧЕК ПРИ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОКACUTE KIDNEY INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONСмирновК. А.SmirnovK. A.noemail@neicon.ruДобронравовВ. А.DobronravovV. A.noemail@neicon.ruПервый Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаРоссияPavlov First Saint Petersburg State Medical UniversityRussian Federation2014011120141862642Copyright © Смирнов К.А., Добронравов В.А., 20142014Смирнов К.А., Добронравов В.А.Smirnov K.A., Dobronravov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/56

На сегодняшний день трансплантация гемопоэтических стволовых клеток (ТГСК) стала распространённым методом лечения различных гематологических заболеваний (злокачественных и незлокачественных), а также солидных опухолей. Тем не менее, выживаемость пациентов может быть серьёзным образом лимитирована ввиду развития специфических осложнений, ассоциированных с ТГСК. Распространённым осложнением ТГСК, ухудшающим исходы трансплантации, как ближайшие, так и отдалённые, является острое повреждение почек (ОПП). В данной статье приведены данные, касающиеся эпидемиологии, этиологии, патогенеза и диагностики ОПП после ТГСК.

Nowadays hematopoietic stem cell transplantation (HSCT) has become a common treatment for various hematological diseases (malignant and nonmalignant) and solid tumors. However, survival in patients can be seriously limited by the development of HSCT-related complications. Acute kidney injury (AKI) is a common complication in patients following HSCT, which seriously affects both short and long-term outcomes. In this article epidemiology, etiology, pathogenesis and diagnostics data of AKI following HSCT are described.

острое повреждение почектрансплантация гемопоэтических стволовых клетоксиндром обструкции синусоидов печениострая реакция трансплантат против хозяинатромботическая микроангиопатиясиндром лизиса опухолевых клетокингибиторы кальциневринаамфотерицин Вацикловираминогликозидыacute kidney injuryhematopoietic stem cell transplantationsinusoidal obstruction syndromeacute graft versus host diseasethrombotic microangiopathytumor lysis syndromecalcineurin inhibitorsamphotericin BacycloviraminoglycosidesReferencesPassweg J.R., Baldomero H. The EBMT activity survey: 19902010. Bone Marrow Transplant 2012;47(7):906-923Passweg J.R., Baldomero H. The EBMT activity survey: 19902010. Bone Marrow Transplant 2012;47(7):906-923www.wbmt.orgwww.wbmt.orgRubenfeld G.D., Crawford S.W. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med1996; 125(8): 625-633Rubenfeld G.D., Crawford S.W. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med1996; 125(8): 625-633Mcdonald G.B., Hinds M.S. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118(4): 255-267Mcdonald G.B., Hinds M.S. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118(4): 255-267George J.N., Li X. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44(2): 294-304George J.N., Li X. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44(2): 294-304Nash R.A., Pepe M.S. Acute Graft-Versus-Host Disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporin and methotrexate Blood1992; 80(7): 1838-1845Nash R.A., Pepe M.S. Acute Graft-Versus-Host Disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporin and methotrexate Blood1992; 80(7): 1838-1845Meijer E., Boland G.J. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003; 16(4): 647-657Meijer E., Boland G.J. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003; 16(4): 647-657Lopes A., Jorge S. Acute kidney injury following HCT: incidence, risk factors and outcome. Bone Marrow transplantation 2011; 46(11): 1399-1408Lopes A., Jorge S. Acute kidney injury following HCT: incidence, risk factors and outcome. Bone Marrow transplantation 2011; 46(11): 1399-1408Parikh C.R., Coca S.G. Acute renal failure in hematopoietic cell transplantation. Kidney Int 2006; 69(3): 430-435Parikh C.R., Coca S.G. Acute renal failure in hematopoietic cell transplantation. Kidney Int 2006; 69(3): 430-435Gruss E., Bernis C. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol 1995; 15(6): 473-479Gruss E., Bernis C. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol 1995; 15(6): 473-479Weiss A.S., Sandmaier B.M. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 2006; 6(1): 89-94Weiss A.S., Sandmaier B.M. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 2006; 6(1): 89-94Singh N., McNeely J. Kidney complications of hematopoietic stem cell transplantation. AJKD 2013; 61(5): 809-821Singh N., McNeely J. Kidney complications of hematopoietic stem cell transplantation. AJKD 2013; 61(5): 809-821Shimoi T., Ando M. The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT. Bone Marrow Transplantation 2013; 48(1): 80-84Shimoi T., Ando M. The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT. Bone Marrow Transplantation 2013; 48(1): 80-84Hingorani S.R., Guthrie K., Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int 2005; 67(1): 272-277Hingorani S.R., Guthrie K., Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int 2005; 67(1): 272-277Zager R.A., O’Quigley J. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989; 13(3): 210-216Zager R.A., O’Quigley J. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989; 13(3): 210-216Zager R.A. Acute renal failure in the setting of bone marrow transplantation. Kidney Int 1994; 46(5): 1443-1458Zager R.A. Acute renal failure in the setting of bone marrow transplantation. Kidney Int 1994; 46(5): 1443-1458Parikh C.R., McSweeney P.A. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 2002; 62(2): 566-573Parikh C.R., McSweeney P.A. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 2002; 62(2): 566-573Gooley T.A., Chien J.W. Reduced mortality after allogeneic hematopoietic cell transplantation. N Engl J Med 2010; 363(22): 2091Gooley T.A., Chien J.W. Reduced mortality after allogeneic hematopoietic cell transplantation. N Engl J Med 2010; 363(22): 2091Helal I., Byzun A. Acute renal failure following allogeneic hematopoietic cell transplantation: incidence, outcome and risk factors. Saudi J Kidney Dis Transpl 2011; 22(3): 437-443Helal I., Byzun A. Acute renal failure following allogeneic hematopoietic cell transplantation: incidence, outcome and risk factors. Saudi J Kidney Dis Transpl 2011; 22(3): 437-443Humphreys B.D., Soiffer R.J. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 2005; 16(1): 151-161Humphreys B.D., Soiffer R.J. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 2005; 16(1): 151-161Parikh C.R., Sandmaier B.M. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol2004; 15(7): 1868-1876Parikh C.R., Sandmaier B.M. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol2004; 15(7): 1868-1876Parikh C.R., Schrier R.W. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 2005; 45(3): 502-509Parikh C.R., Schrier R.W. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 2005; 45(3): 502-509Gale R.P., Horowitz M.M. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120(8): 646-652Gale R.P., Horowitz M.M. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120(8): 646-652Parikh C.R., McSweeney P. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int 2005; 67(5): 1999-2005Parikh C.R., McSweeney P. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int 2005; 67(5): 1999-2005Hahn T., Rondeau C. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 2003; 32(4): 405-410Hahn T., Rondeau C. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 2003; 32(4): 405-410Pallera A.M., Schwartzberg L.S. Managing the toxicity of hematopoietic stem cell transplant. J Support Oncol 2004; 2(3): 223-247Pallera A.M., Schwartzberg L.S. Managing the toxicity of hematopoietic stem cell transplant. J Support Oncol 2004; 2(3): 223-247EBMT Handbook: EBMT-ESH Handbook on Haemopoietic Stem Cell Transplantation, 2012; 221-223EBMT Handbook: EBMT-ESH Handbook on Haemopoietic Stem Cell Transplantation, 2012; 221-223Calne R.Y., White D.J. Cyclosporin A in patients receiving renal allografts from cadaver donors Lancet 1978; 2(8104-8105): 1323-1327Calne R.Y., White D.J. Cyclosporin A in patients receiving renal allografts from cadaver donors Lancet 1978; 2(8104-8105): 1323-1327Powles R.L., Clink H.M. Cyclosporin A to prevent graft-versushost disease in man after allogeneic bone-marrow transplantation-Lancet 1980; 1(8164): 327-329Powles R.L., Clink H.M. Cyclosporin A to prevent graft-versushost disease in man after allogeneic bone-marrow transplantation-Lancet 1980; 1(8164): 327-329Смирнов А.В. Лечение гломерулопатий циклоспорином: правильный подход с неверным обоснованием. Нефрология, 2010; 14(4): 9-22Смирнов А.В. Лечение гломерулопатий циклоспорином: правильный подход с неверным обоснованием. Нефрология, 2010; 14(4): 9-22Shaw K.T., Ho A.M. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995; 92(24): 11205-11209Shaw K.T., Ho A.M. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995; 92(24): 11205-11209Bobadilla N.A., Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 2007; 293(1): F2-F9Bobadilla N.A., Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 2007; 293(1): F2-F9Bobadilla N.A., Gamba G. Role of NO in cyclosporin nephrotoxicity: effects of chronic NO inhibition and NO synthases gene expression. Am J Physiol Renal Physiol 1998; 274(4): F791-F798Bobadilla N.A., Gamba G. Role of NO in cyclosporin nephrotoxicity: effects of chronic NO inhibition and NO synthases gene expression. Am J Physiol Renal Physiol 1998; 274(4): F791-F798Kon V., Sugiura M., Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37(6): 1487-1491Kon V., Sugiura M., Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37(6): 1487-1491Perico N., Benigni A. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am J Physiol Renal Fluid Electrolyte Physiol 1986; 251(4): F581- F587Perico N., Benigni A. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am J Physiol Renal Fluid Electrolyte Physiol 1986; 251(4): F581- F587Perico N., Benigni A. Acute cyclosporine A nephrotoxicity in rats: which role for renin- angiotensin system and glomerular prostaglandins? Clin Nephrol 1986; 25(1): S83-S88Perico N., Benigni A. Acute cyclosporine A nephrotoxicity in rats: which role for renin- angiotensin system and glomerular prostaglandins? Clin Nephrol 1986; 25(1): S83-S88Diederich D., Yang Z. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 1992; 2(8): 1291-1297Diederich D., Yang Z. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 1992; 2(8): 1291-1297Pichler R.H., Franceschini N. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6(4): 1186-1196Pichler R.H., Franceschini N. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6(4): 1186-1196Shihab F.S., Bennett W.M. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine ne- phropathy. Kidney Int 1997.52(3): 660-673Shihab F.S., Bennett W.M. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine ne- phropathy. Kidney Int 1997.52(3): 660-673Lopez-Ongil S., Saura M. Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 1996; 271(3): H1072-H1078Lopez-Ongil S., Saura M. Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 1996; 271(3): H1072-H1078Zhong Z., Arteel G.E. Cyclosporin A increases hypoxia and free radical production in rat kidneys: pre- vention by dietary glycine. Am J Physiol Renal Physiol 1998; 275(4): F595- F604Zhong Z., Arteel G.E. Cyclosporin A increases hypoxia and free radical production in rat kidneys: pre- vention by dietary glycine. Am J Physiol Renal Physiol 1998; 275(4): F595- F604Zhong Z., Connor H.D. Dietary glycine and renal denervation prevents cyclosporin A-induced hydroxyl radical production in rat kidney. Mol Pharmacol 1999; 561(3): 455- 463Zhong Z., Connor H.D. Dietary glycine and renal denervation prevents cyclosporin A-induced hydroxyl radical production in rat kidney. Mol Pharmacol 1999; 561(3): 455- 463Feria I., Pichardo I. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63(1): 43-52Feria I., Pichardo I. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63(1): 43-52Ling H., Li X. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003; 14(2): 377-388Ling H., Li X. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003; 14(2): 377-388Verburgh CA., Vermeij CG. Haemolytic uraemic syndrome following bone marrow transplantation: Case report and review of the literature. Nephrol Dial Transplant 1996; 11(7): 1332-1337Verburgh CA., Vermeij CG. Haemolytic uraemic syndrome following bone marrow transplantation: Case report and review of the literature. Nephrol Dial Transplant 1996; 11(7): 1332-1337Holler E., Kolb H.J. Microangiopathy in patients on cyclosponne prophylaxis who developed acute graft-versus- host disease after HLA-identical bone marrow transplantation. Blood 1989; 73(7): 2018-2024Holler E., Kolb H.J. Microangiopathy in patients on cyclosponne prophylaxis who developed acute graft-versus- host disease after HLA-identical bone marrow transplantation. Blood 1989; 73(7): 2018-2024Yoshinobu Kanda, Rie Hyo. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol 2006; 81(11): 838-844Yoshinobu Kanda, Rie Hyo. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol 2006; 81(11): 838-844Ruutu T., Niederwieser D. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow transplantation (EBMT). Bone Marrow Transplantation 1997; 19(8): 759-764Ruutu T., Niederwieser D. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow transplantation (EBMT). Bone Marrow Transplantation 1997; 19(8): 759-764Jankauskiene A., Druskis V. Cyclosporine nephrotoxicity: associated allograft dysfunction at low through concentration. Clin Nephrol 2001; 56(6): S27-S29Jankauskiene A., Druskis V. Cyclosporine nephrotoxicity: associated allograft dysfunction at low through concentration. Clin Nephrol 2001; 56(6): S27-S29Rex J.H., Bennett J.E. A randomized trial compareing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia: Candidemia Study Group and the National Institute. N Engl J Med 1994; 331(20): 1325-1330Rex J.H., Bennett J.E. A randomized trial compareing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia: Candidemia Study Group and the National Institute. N Engl J Med 1994; 331(20): 1325-1330Bates D.W., Su L. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32(5): 686-693Bates D.W., Su L. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32(5): 686-693Wingard J.R., Beals S.U. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987; 2(2): 175-181Wingard J.R., Beals S.U. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987; 2(2): 175-181Karabinis A., Hill C. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988; 26(3): 429-432Karabinis A., Hill C. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988; 26(3): 429-432Sable C.A., Donowitz G.R. Infection in bone marrow transplant recipients. Clin Infect Dis 1994; 18(3): 273-281Sable C.A., Donowitz G.R. Infection in bone marrow transplant recipients. Clin Infect Dis 1994; 18(3): 273-281Denning D.W., Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12(6): 1147-1201Denning D.W., Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12(6): 1147-1201Goodman J.L., Winston D.J. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326(13): 845-851Goodman J.L., Winston D.J. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326(13): 845-851Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemoter 2002; 49 [Suppl 1]: 7-10Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemoter 2002; 49 [Suppl 1]: 7-10Brajtburg J., Bolard J. Carrier effects on biological activity of Amphotericin B. Clin Microbiol Rev 1996; 9(4): 512-31Brajtburg J., Bolard J. Carrier effects on biological activity of Amphotericin B. Clin Microbiol Rev 1996; 9(4): 512-31R. Laniado-Laborin, M.N. Cabrales-Vargas. Amphotericin B: side effects and toxicity Rev Iberoam Micol. 2009; 26(4): 223-227R. Laniado-Laborin, M.N. Cabrales-Vargas. Amphotericin B: side effects and toxicity Rev Iberoam Micol. 2009; 26(4): 223-227Wingard J.R., Kubilis P. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clinical Infectious Disease1999; 29(6): 1402-1407Wingard J.R., Kubilis P. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clinical Infectious Disease1999; 29(6): 1402-1407Deray G. Amphotericin B nephrotoxicity. Journal of antimicrobial chemotherapy2002; 49[Suppl 1]: 37-41Deray G. Amphotericin B nephrotoxicity. Journal of antimicrobial chemotherapy2002; 49[Suppl 1]: 37-41Branch R.A. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148(11): 2389-2394Branch R.A. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148(11): 2389-2394Heidemann H.T., Gerkens J.F. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75(3): 476-481Heidemann H.T., Gerkens J.F. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75(3): 476-481Luber A.D., Maa L., Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999; 43(2): 267-271Luber A.D., Maa L., Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999; 43(2): 267-271ISSN 1561-6274. Нефрология. 2014. Том 18. №6.ISSN 1561-6274. Нефрология. 2014. Том 18. №6.Shulman H., Striker G. Nephrotoxicity of cyclosporinA after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med 1981; 305(23): 1392-1395Shulman H., Striker G. Nephrotoxicity of cyclosporinA after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med 1981; 305(23): 1392-1395Ohnishi A., Ohnishi T., Sodium status influences chronic Amphotericin B nephrotoxicity in rats. Antimicrob Agents Chemother 1989; 33(8): 1222-1227Ohnishi A., Ohnishi T., Sodium status influences chronic Amphotericin B nephrotoxicity in rats. Antimicrob Agents Chemother 1989; 33(8): 1222-1227Gerkens J.F., Branch R.A. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther 1980; 214(2): 306-311Gerkens J.F., Branch R.A. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther 1980; 214(2): 306-311KDIGO AKI Guideline, vol. 2, issue 1, 2012KDIGO AKI Guideline, vol. 2, issue 1, 2012Craig M., Cumpston A.D. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantational unit. Bone Marrow Transplantation 2007; 39(8): 477-482Craig M., Cumpston A.D. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantational unit. Bone Marrow Transplantation 2007; 39(8): 477-482Maschmeyer G., Ljungman P. Infections in hematopoietic stem cell transplant recipients. A. Safdar (ed.), Principles and Practice of Cancer Infectious Diseases, Current Clinical 0ncology, 2011Maschmeyer G., Ljungman P. Infections in hematopoietic stem cell transplant recipients. A. Safdar (ed.), Principles and Practice of Cancer Infectious Diseases, Current Clinical 0ncology, 2011Kruger W.H., Kiefer T. Aminoglycoside-free interventional antibiotic management in patients undergoing haemopoietic stem cell transplantation. GMS Krankenhhyg Interdiszip. 2010; 5(2)Kruger W.H., Kiefer T. Aminoglycoside-free interventional antibiotic management in patients undergoing haemopoietic stem cell transplantation. GMS Krankenhhyg Interdiszip. 2010; 5(2)Martinez-Salgado C., Lopez-Hernandez F.J. Glomerular nephrotoxicity of aminoglycosides. Toxicology and applied pharmacology 2007; 223(1): 86-98Martinez-Salgado C., Lopez-Hernandez F.J. Glomerular nephrotoxicity of aminoglycosides. Toxicology and applied pharmacology 2007; 223(1): 86-98Nagai, J., Takano, M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab. Pharmacokineti2004; 19(3): 159-170Nagai, J., Takano, M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab. Pharmacokineti2004; 19(3): 159-170Shakil S., Khan R. Aminoglycosides versus bacteria-a description of the action, resistance mechanism, and nosocomial battleground. Journal of Biomedical Science 2008; 15(1): 5-14Shakil S., Khan R. Aminoglycosides versus bacteria-a description of the action, resistance mechanism, and nosocomial battleground. Journal of Biomedical Science 2008; 15(1): 5-14Oliveira J.F.P., Silva C.A. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrobial agents and chemotherapy 2009; 53(7): 2887-2891Oliveira J.F.P., Silva C.A. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrobial agents and chemotherapy 2009; 53(7): 2887-2891Lopez-Novoa J.M., Quiros Yaremi. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney International 2011; 79(1): 33-45Lopez-Novoa J.M., Quiros Yaremi. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney International 2011; 79(1): 33-45Добронравов В.А. Патофизиология острого повреждения почек (книга “Острое повреждение почек”, в печати, 2014 гДобронравов В.А. Патофизиология острого повреждения почек (книга “Острое повреждение почек”, в печати, 2014 гKing D.H. History, pharmacokinetics, and pharmacology of acyclovir. J Am Acad Dermatol. 1988; 18(1): 176-179King D.H. History, pharmacokinetics, and pharmacology of acyclovir. J Am Acad Dermatol. 1988; 18(1): 176-179Fyfe J.A., Keller P.M. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound 9-(2-hydroxyethoxymethyl) guanine. J Biol Chem 1978; 253(24): 8721-8727Fyfe J.A., Keller P.M. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound 9-(2-hydroxyethoxymethyl) guanine. J Biol Chem 1978; 253(24): 8721-8727Miller W.H., Miller R.L. Phosphorylation of acyclovir (acy-cloguanosine) monophosphate by GMP kinase. J Biol Chem 1980; 255(15): 7204-7207Miller W.H., Miller R.L. Phosphorylation of acyclovir (acy-cloguanosine) monophosphate by GMP kinase. J Biol Chem 1980; 255(15): 7204-7207Perazella M.A. Crystal-induced acute renal failure. Am J Med 1999; 106(4): 459-465Perazella M.A. Crystal-induced acute renal failure. Am J Med 1999; 106(4): 459-465Gunness P., Alexa K. Acyclovir-induced nephrotoxicity: the role of acyclovir aldehyde metabolite. Transl Res 2011; 158(5): 290-301Gunness P., Alexa K. Acyclovir-induced nephrotoxicity: the role of acyclovir aldehyde metabolite. Transl Res 2011; 158(5): 290-301Selzer G., Parker G.F. Senecio poisoning exhibiting as chiaris syndrome Am J Pathol 1950; 27: 885-907Selzer G., Parker G.F. Senecio poisoning exhibiting as chiaris syndrome Am J Pathol 1950; 27: 885-907Jacobs P., Miller J L. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukemia. S Afr Med J 1979; 55(1): 5-10Jacobs P., Miller J L. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukemia. S Afr Med J 1979; 55(1): 5-10Carreras E., Bertz H. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92(10): 3599-3604Carreras E., Bertz H. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92(10): 3599-3604Carreras E., Granena A. Hepatic venoocclusive disease after bone marrow transplantation. Blood Reviews 1993; 7(1): 43-51Carreras E., Granena A. Hepatic venoocclusive disease after bone marrow transplantation. Blood Reviews 1993; 7(1): 43-51Carreras E. Veno-occlusive disease of the liver after hematopoietic cell transplantation. Eu J Haematol 2000; 64(5): 281-291Carreras E. Veno-occlusive disease of the liver after hematopoietic cell transplantation. Eu J Haematol 2000; 64(5): 281-291DeLeve L.D., Shulman H.M. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease)Semin Liver Dis 2002; 22(1): 27-42DeLeve L.D., Shulman H.M. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease)Semin Liver Dis 2002; 22(1): 27-42Ho V.T., Linden E. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Review and update on the use of defibrotide. Semin Thromb Hemost 2007; 33(4): 373-388Ho V.T., Linden E. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Review and update on the use of defibrotide. Semin Thromb Hemost 2007; 33(4): 373-388Carreras E. Early complications after HSCT. The EBMT Handbook revised edition. 2008; 180-197Carreras E. Early complications after HSCT. The EBMT Handbook revised edition. 2008; 180-197Fink J.C., Cooper M.A. Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced “hepatorenal syndrome”. Am Soc Nephrol 1995; 6(6): 1655-1660Fink J.C., Cooper M.A. Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced “hepatorenal syndrome”. Am Soc Nephrol 1995; 6(6): 1655-1660Sawinski D. The kidney effects of hematopoietic stem cell transplantation. Advances in chronic kidney disease. 2014; 21(1): 96-105Sawinski D. The kidney effects of hematopoietic stem cell transplantation. Advances in chronic kidney disease. 2014; 21(1): 96-105Kumar S., DeLeve L.D. Hepatic Veno-occlusive Disease (Sinusoidal obstruction syndrome) after hematopoietic stem cell transpalntation. Mayo Clin Proc2003; 78(5): 589-598Kumar S., DeLeve L.D. Hepatic Veno-occlusive Disease (Sinusoidal obstruction syndrome) after hematopoietic stem cell transpalntation. Mayo Clin Proc2003; 78(5): 589-598Lee S.J., Klein J. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110(13): 4576-4583Lee S.J., Klein J. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110(13): 4576-4583Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J. et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11(12): 945-956Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J. et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11(12): 945-956Nelson J. Chao, Clinical manifestations, diagnosis and grading of acute graft-versus-host disease. Upto Date 2013Nelson J. Chao, Clinical manifestations, diagnosis and grading of acute graft-versus-host disease. Upto Date 2013Deeg H.J., Henslee-Downey P.J. Management of acute graft-versus-host disease. Bone Marrow Transplant 1990; 6(1): 1-8 Copelan E.A., Hematopoietic stem cell transplantation. N Engl J Med 2006; 354(17): 1813-1826Deeg H.J., Henslee-Downey P.J. Management of acute graft-versus-host disease. Bone Marrow Transplant 1990; 6(1): 1-8 Copelan E.A., Hematopoietic stem cell transplantation. N Engl J Med 2006; 354(17): 1813-1826Ball L.M., Egeler R.M. Acute GVHD: pathogenesis and classification. Bone Marrow Transplantation 2008; 41[Suppl 2] S58-S64Ball L.M., Egeler R.M. Acute GVHD: pathogenesis and classification. Bone Marrow Transplantation 2008; 41[Suppl 2] S58-S64Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 2003; 21(4): 149-161Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 2003; 21(4): 149-161Homma C.I., Kami M., Graft-versus-host disease of the kidney after rapid tapering of cyclosporin following reduced intensity hematopoietic stem cell transplantation. Bone marrow transplantation 2005; 35(9): 929-930Homma C.I., Kami M., Graft-versus-host disease of the kidney after rapid tapering of cyclosporin following reduced intensity hematopoietic stem cell transplantation. Bone marrow transplantation 2005; 35(9): 929-930Kersting S., Dorp S.V. Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 2008; 14(1): 125-131Kersting S., Dorp S.V. Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 2008; 14(1): 125-131Pidala J. Graft-vs-host disease following allogeneic hematopoietic stem cell transplantation. Cancer Control 2011; 18(4): 268-276Pidala J. Graft-vs-host disease following allogeneic hematopoietic stem cell transplantation. Cancer Control 2011; 18(4): 268-276Richard A. Larson, Ching-Hon Pui. Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors. Upto Date 2013Richard A. Larson, Ching-Hon Pui. Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors. Upto Date 2013Fleming D.R., Doukas M.A. Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma1992; 8(4-5): 315-318Fleming D.R., Doukas M.A. Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma1992; 8(4-5): 315-318Kalemkerian G.P., Darwish B. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med1997; 103(5): 363-367Kalemkerian G.P., Darwish B. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med1997; 103(5): 363-367Howard S.C., Deborah P. The tumor lysis syndrome. N Engl J Med 2011; 364(19): 1844-1854Howard S.C., Deborah P. The tumor lysis syndrome. N Engl J Med 2011; 364(19): 1844-1854Coiffier B., Altman A. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26(16): 2767-2778Coiffier B., Altman A. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26(16): 2767-2778Cairo M.S., Coiffier B. Recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149(4): 578-586Cairo M.S., Coiffier B. Recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149(4): 578-586Band P.R., Silverberg D.S. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970; 283(7): 354-357Band P.R., Silverberg D.S. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970; 283(7): 354-357Deconti R.C., Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966; 274(9): 481-486Deconti R.C., Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966; 274(9): 481-486Hande K.R., Hixson C.V. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res 1981; 41(6): 2273-2279Hande K.R., Hixson C.V. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res 1981; 41(6): 2273-2279LaRosa C., McMullen L. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007; 22(1): 132-135LaRosa C., McMullen L. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007; 22(1): 132-135Pais V.M., Lowe G. Xanthine urolithiasis. Urology 2006; 67(5): 1084Pais V.M., Lowe G. Xanthine urolithiasis. Urology 2006; 67(5): 1084Conger J.D., Falk S.A. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 1977; 59(5): 786-793Conger J.D., Falk S.A. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 1977; 59(5): 786-793Moake J.L. Thrombotic microangiopathies. N Engl J Med 2002 347: 589-600Moake J.L. Thrombotic microangiopathies. N Engl J Med 2002 347: 589-600Van der Plas R.M., Schiphorst M.E. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93(11): 3798-3802Van der Plas R.M., Schiphorst M.E. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93(11): 3798-3802Stavrou E., Lazarous H.M. Thrombotic microangiopathy in haematopoietic stem cell transplantation: an update. Medit J Hemat Infect Dis 2010, 2(3): e2010033Stavrou E., Lazarous H.M. Thrombotic microangiopathy in haematopoietic stem cell transplantation: an update. Medit J Hemat Infect Dis 2010, 2(3): e2010033Kim S.S., Patel M. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion. 2014Kim S.S., Patel M. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion. 2014Sadler J.E. Thrombotic thrombocytopenic purpura: a moving target. Hematology Am SocHematol Educ Program 2006: 415-420Sadler J.E. Thrombotic thrombocytopenic purpura: a moving target. Hematology Am SocHematol Educ Program 2006: 415-420Stavrou E., Lazarus H.M., Thrombotic microangiopathy in haematopoietic stem cell transplantation: an update. Medit J Hemat Infect Dis 2010; 2(3)Stavrou E., Lazarus H.M., Thrombotic microangiopathy in haematopoietic stem cell transplantation: an update. Medit J Hemat Infect Dis 2010; 2(3)Jodele S., Davies S.M. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124(4): 645-653Jodele S., Davies S.M. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124(4): 645-653Kentouche K., Zintl F. von Willebrand factor-cleaving protease (ADAMTS 13) in the course of stem cell transplantation. Semin Thromb Hemost 2006; 32(2): 98-104Kentouche K., Zintl F. von Willebrand factor-cleaving protease (ADAMTS 13) in the course of stem cell transplantation. Semin Thromb Hemost 2006; 32(2): 98-104Zeigler Z.R., Rosenfeld C.S. Plasma von Willebrand Factor Antigen (vWF: AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolitic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). Am J Hematol 1996; 53(4): 213-220Zeigler Z.R., Rosenfeld C.S. Plasma von Willebrand Factor Antigen (vWF: AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolitic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). Am J Hematol 1996; 53(4): 213-220Cohen H., Bull H.A. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Haematol 1989; 43(3): 207-214Cohen H., Bull H.A. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Haematol 1989; 43(3): 207-214Gordon B.G., Haire W.D. Protein C deficiency following hematopoietic stem cell transplantation: optimization of intavenous vitamin K dose. Bone Marrow Transplant 1993; 12(1): 73-76Gordon B.G., Haire W.D. Protein C deficiency following hematopoietic stem cell transplantation: optimization of intavenous vitamin K dose. Bone Marrow Transplant 1993; 12(1): 73-76Hoorn C.M., Wagner J.G. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol 1995; 130(1): 87-94Hoorn C.M., Wagner J.G. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol 1995; 130(1): 87-94Kohn S., Fradis M. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct Pathol 1997; 21(3): 289-299Kohn S., Fradis M. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct Pathol 1997; 21(3): 289-299Ngaya S., Wada H. Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. Am J Hematol 1995; 50(4): 237-243Ngaya S., Wada H. Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. Am J Hematol 1995; 50(4): 237-243Chow A.Y., Chin C. Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol 2006; 24(6): 925-928Chow A.Y., Chin C. Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol 2006; 24(6): 925-928Fajardo L.F. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005; 44(1): 13-22Fajardo L.F. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005; 44(1): 13-22Takatsuka H., Wakae T. Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant 2003; 31(6): 475-479Takatsuka H., Wakae T. Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant 2003; 31(6): 475-479Matsuda X., Hara J. Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children. Bone Marrow Transplant 1999; 24(8): 919-923Matsuda X., Hara J. Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children. Bone Marrow Transplant 1999; 24(8): 919-923Biedermann B.C., Sahner S. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359(9323): 2078-2083Biedermann B.C., Sahner S. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359(9323): 2078-2083Salat C., Holler E. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplant 1997; 19(9): 909-914Salat C., Holler E. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplant 1997; 19(9): 909-914George J.N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96(4): 1223-1229George J.N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96(4): 1223-1229Ho V.T., Cutler C. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transpantation. Biol Blood Marrow Transplant 2005; 11(8): 571-575Ho V.T., Cutler C. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transpantation. Biol Blood Marrow Transplant 2005; 11(8): 571-575Ruutu T., Barosi G. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international Working group. Haematologica 2007; 92(1): 95-100Ruutu T., Barosi G. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international Working group. Haematologica 2007; 92(1): 95-100Roy V., Rizvi M.A. Thrombotic thrombocytopenic purpuralike syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27(6): 641-646Roy V., Rizvi M.A. Thrombotic thrombocytopenic purpuralike syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27(6): 641-646Changsirikulchai S., Myerson D. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol2009; 4(2): 345-353Changsirikulchai S., Myerson D. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol2009; 4(2): 345-353Noel C., Hazzan M. Renal failure and bone marrow transplantation. Nephrol Dial Transplant 1998; 13(10): 2464-2466Noel C., Hazzan M. Renal failure and bone marrow transplantation. Nephrol Dial Transplant 1998; 13(10): 2464-2466Hale G.A., Rochester R.J. Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: Characteristics and outcome. Biol Blood Marrow Transplant 2003; 9(11): 698 -705Hale G.A., Rochester R.J. Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: Characteristics and outcome. Biol Blood Marrow Transplant 2003; 9(11): 698 -705Fink J.C., Cooper M.A. Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced “hepatorenal syndrome”. J Am Soc Nephrol 1995; 6(6): 1655-1660Fink J.C., Cooper M.A. Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced “hepatorenal syndrome”. J Am Soc Nephrol 1995; 6(6): 1655-1660Morito T., Ando M. Early identification of acute kidney injury after hematopoietic stem cell transplantation by the measurment of urinary biomarkers. Nihon Jinzo Gakkai Shi 2011; 53(8): 1150-1158Morito T., Ando M. Early identification of acute kidney injury after hematopoietic stem cell transplantation by the measurment of urinary biomarkers. Nihon Jinzo Gakkai Shi 2011; 53(8): 1150-1158Murray P.T., Mehta R.L. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int 2014; 85(3): 513-521Murray P.T., Mehta R.L. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int 2014; 85(3): 513-521Lopes J.A., Jorge S. Acute kidney injury in patients with sepsis: a contemporary analysis. Int J Infect Dis 2009; 13(2): 176-181Lopes J.A., Jorge S. Acute kidney injury in patients with sepsis: a contemporary analysis. Int J Infect Dis 2009; 13(2): 176-181Covic A., Shiller A. The impact of acute kidney injury on short-term survival in an Eastern European population with stroke. Nephrol Dial Transplant 2008; 23(7): 2228-2234Covic A., Shiller A. The impact of acute kidney injury on short-term survival in an Eastern European population with stroke. Nephrol Dial Transplant 2008; 23(7): 2228-2234Lopes J.A., Goncalves S. Contemporary analysis of the influence of acute kidney injury after reduced intensity conditioning haematopoietic cell transplantation on long-term survival. Bone Marrow Transplant. 2008; 42(9): 619-626Lopes J.A., Goncalves S. Contemporary analysis of the influence of acute kidney injury after reduced intensity conditioning haematopoietic cell transplantation on long-term survival. Bone Marrow Transplant. 2008; 42(9): 619-626Pinana J.L., Valcarcel D. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience. Blood Marrow Transplant 2009; 15(1): 21-29Pinana J.L., Valcarcel D. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience. Blood Marrow Transplant 2009; 15(1): 21-29Parikh C.R., Yarlagadda S.G. Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008; 14(3): 309-315Parikh C.R., Yarlagadda S.G. Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008; 14(3): 309-315Ellis M.J., Parikh C.R. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transplant 2008; 8(11): 2378-2390Ellis M.J., Parikh C.R. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transplant 2008; 8(11): 2378-2390Tonelli M., Wiebe N. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17(7): 2034-2047Tonelli M., Wiebe N. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17(7): 2034-2047Al-Hazzouri A., Cao Q. Similar risk for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14(6): 658-663Al-Hazzouri A., Cao Q. Similar risk for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14(6): 658-663Kersting S., Verdonck L.F. Stem cell transplantation nephropathy: a report of six cases. Biol Blood Marrow Transplant 2007; 13(6): 638-643Kersting S., Verdonck L.F. Stem cell transplantation nephropathy: a report of six cases. Biol Blood Marrow Transplant 2007; 13(6): 638-643Carreras E., Diaz-Ricart M. The role of endothelium in the short-term complications of HCT. Bone Marrow Transplantation 2011; 46(12): 1495-1502Carreras E., Diaz-Ricart M. The role of endothelium in the short-term complications of HCT. Bone Marrow Transplantation 2011; 46(12): 1495-1502Smirnov A.V., Kaiukov I.G., Dobronravov V.A. Ostroe povrezhdenie pochek i ostraia pochechnaia nedostatochnost': nekotory'e uroki mezhdunarodny'kh initciativ. Nefrologiia 2008; 12(3) [Smirnov A.V., Kaiukov I.G., Dobronravov V.A. Ostroe povrezhdenie pochek i ostraia pochechnaia nedostatochnost': nekotory'e uroki mezhdunarodny'kh initciativ. Nefrologiia 2008; 12(3)]Smirnov A.V., Kaiukov I.G., Dobronravov V.A. Ostroe povrezhdenie pochek i ostraia pochechnaia nedostatochnost': nekotory'e uroki mezhdunarodny'kh initciativ. Nefrologiia 2008; 12(3) [Smirnov A.V., Kaiukov I.G., Dobronravov V.A. Ostroe povrezhdenie pochek i ostraia pochechnaia nedostatochnost': nekotory'e uroki mezhdunarodny'kh initciativ. Nefrologiia 2008; 12(3)]

The authors declare that there are no conflicts of interest present.